These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 98419)
1. Effect of alrestatin on arginine-induced secretion of glucagon and insulin in the rat. Lippmann W; Kobric M Horm Metab Res; 1978 Jul; 10(4):280-2. PubMed ID: 98419 [TBL] [Abstract][Full Text] [Related]
2. Susceptibility of aldehyde and aldose reductases of human tissues to aldose reductase inhibitors. Srivastava SK; Petrash JM; Sadana IJ; Ansari NH; Partridge CA Curr Eye Res; 1982-1983; 2(6):407-10. PubMed ID: 6820339 [TBL] [Abstract][Full Text] [Related]
3. Human placenta aldose reductase. Forms sensitive and insensitive to inhibition by alrestatin. Maragoudakis ME; Wasvary J; Hankin H; Gargiulo P Mol Pharmacol; 1984 May; 25(3):425-30. PubMed ID: 6427599 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of aldehyde reductase by aldose reductase inhibitors. Sato S; Kador PF Biochem Pharmacol; 1990 Sep; 40(5):1033-42. PubMed ID: 2117925 [TBL] [Abstract][Full Text] [Related]
5. N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor. Sestanj K; Bellini F; Fung S; Abraham N; Treasurywala A; Humber L; Simard-Duquesne N; Dvornik D J Med Chem; 1984 Mar; 27(3):255-6. PubMed ID: 6422042 [No Abstract] [Full Text] [Related]
6. Efficacy of Alrestatin, an aldose reductase inhibitor, in human diabetic and nondiabetic lenses. Chylack LT; Henriques HF; Cheng HM; Tung WH Ophthalmology; 1979 Sep; 86(9):1579-85. PubMed ID: 121768 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of human brain aldose reductase and hexonate dehydrogenase by alrestatin and sorbinil. O'Brien MM; Schofield PJ; Edwards MR J Neurochem; 1982 Sep; 39(3):810-4. PubMed ID: 6808090 [TBL] [Abstract][Full Text] [Related]
8. The effect of alrestatin on alanine-stimulated release of insulin and glucagon in man. Distiller LA; Joffe BI; Sandler M; Kark A; Seftel HC J Endocrinol Invest; 1981; 4(1):115-7. PubMed ID: 6787107 [TBL] [Abstract][Full Text] [Related]
9. Differences in the susceptibility of various aldose reductases to inhibition. II. Kador PF; Kinoshita JH; Tung WH; Chylack LT Invest Ophthalmol Vis Sci; 1980 Aug; 19(8):980-2. PubMed ID: 6773903 [TBL] [Abstract][Full Text] [Related]
10. Alrestatin: gastric acid antisecretory-antiulcer activity in the rat. Lippmann W; Seethaler K; Borella LE; Pugsley TA Digestion; 1978; 18(1-2):35-44. PubMed ID: 103765 [TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of 2-(arylamino)-4(3H)-quinazolinones as novel inhibitors of rat lens aldose reductase. DeRuiter J; Brubaker AN; Millen J; Riley TN J Med Chem; 1986 May; 29(5):627-9. PubMed ID: 3084783 [TBL] [Abstract][Full Text] [Related]
12. [Inhibition of aldose reductase from the rat lens by flavonoids]. Xie MZ; Shen ZF Yao Xue Xue Bao; 1986 Oct; 21(10):721-4. PubMed ID: 3107341 [No Abstract] [Full Text] [Related]
13. Inhibition of lens aldose reductase by Labiatae flavonoids. Tomás-Barberán FA; López-Gómez C; Villar A; Tomás-Lorente F Planta Med; 1986 Jun; (3):239-40. PubMed ID: 3092256 [No Abstract] [Full Text] [Related]
14. Effect of alrestatin sodium on glucose-stimulated insulin secretion in the fasted anaesthetized rat. Kobric M; Lippmann W Horm Metab Res; 1978 Nov; 10(6):495-500. PubMed ID: 744568 [TBL] [Abstract][Full Text] [Related]
15. [Effects of M79175, an aldose reductase inhibitor, on experimental sugar cataracts]. Ono H; Nozawa Y; Hayano S Nippon Ganka Gakkai Zasshi; 1982; 86(9):1343-50. PubMed ID: 6818854 [No Abstract] [Full Text] [Related]